Axsome医疗 AXSM 深 沪
等待开盘 10-08 09:30:00 美东时间
118.40
-1.540
-1.28%
华盛通- 最 高120.785
- 今 开119.81
- 成交量 22.71万股
- 最 低 117.50
- 昨 收 119.94
- 总市值 58.30亿
- 52周最高 139.1299
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 75.56
- 委 比 -60.00%
- 总股本 4923.64万
- 历史最高 139.1299
- 量 比 0.58
- 振 幅 2.74%
- 历史最低 1.94
- 每 手 1
- 风险率 9.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
B. Riley Securities Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $179
B. Riley Securities analyst Madison El-Saadi initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and announces Price Target of $179.
10-01 22:33
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Axsome Therapeutics announced six poster presentations at Psych Congress 2025, focusing on major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea. The presentations include clinical and real-world data across its neuroscience portfolio, featuring expert consensus recommendations, Phase 3 trial results, and subgroup analyses. The company aims to advance treatments for CNS disorders, addressing unmet needs...
09-17 11:00
“生物科技大牛股猎手”Needham押宝这家“AI+新药研发”领军者 押注股价将狂飙68%
Needham 维持对 Recursion Pharmaceuticals 的“买入”评级，目标价维持在8美元。
09-16 12:10
Wells Fargo Assumes Axsome Therapeutics at Overweight, Announces Price Target of $163
Wells Fargo analyst Benjamin Burnett assumes Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announces Price Target of $163.
09-03 20:51
Axsome Therapeutics Receives Paragraph IV Certification Notice
The latest update is out from Axsome Therapeutics ( ($AXSM) ). On August 19, 20...
08-21 05:28
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.
08-18 21:45
Axsome Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Axsome Therapeutics shares are trading higher after the company reported better...
08-04 20:33
Needham Reiterates Buy on Axsome Therapeutics, Maintains $150 Price Target
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.
08-04 20:02
Axsome Therapeutics Reports Strong Q2 2025 Performance
An update from Axsome Therapeutics ( ($AXSM) ) is now available. On August 4, 2...
08-04 19:58
